- Home
- MATH vs NRXP Comparison
MATH vs NRXP Comparison
Compare MATH & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MATH | NRXP |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 54.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | MATH | NRXP |
|---|---|---|
| Price | $1.15 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 72.5K | ★ 489.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | $3.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.58 |
| 52 Week High | $4.17 | $3.84 |
Technical Indicators
Market Signals| Indicator | MATH | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.09 | 39.99 |
| Support Level | $1.10 | $1.65 |
| Resistance Level | $4.04 | $1.99 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 20.00 | 15.87 |
Price Performance
Historical ComparisonAbout MATH Metalpha Technology Holding Limited
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.